12-甲基-2,5,8,11-四氧杂十三烷 | 63095-27-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 12-甲基-2,5,8,11-四氧杂十三烷
• 英文名称: 12-Methyl-2,5,8,11-tetraoxatridecane
• 英文别名: 2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]propane
• CAS: 63095-27-2
• 化学式: C₁₀H₂₂O₄
• 分子量: 206.28
• InChiKey: VIQKXLIYROUVRO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  36.9
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• TERMINALLY MODIFIED POLYBRANCHED POLYIMIDE, METAL-PLATED TERMINALLY MODIFIED POLYBRANCHED POLYIMIDE, AND METHOD FOR PRODUCING THE SAME
  申请人：Ataka Kikuo

  公开号：US20100009206A1

  公开（公告）日：2010-01-14

  A terminally-modified polybranched polyimide which can be efficiently complexed with an inorganic material is obtained by reacting a component (a): tetracarboxylic dianhydride; a component (b): as an amine component, a mixture of a triamine and a diamine (which may be composed of a triamine only); and a component (c): as a terminal component, a compound selected from general formulae (1-1) to (1-4). H 2 N—X—R 1 (1-1) (In the formula, X represents a single bond or an alkylene group having 1 to 3 carbon atoms, and R 1 represents a nitrogen-containing heterocyclic group). H 2 N—X—R 1 (1-2) (In the formula, X is as defined above, and R 1 represents a sulfur-containing heterocyclic group or an aryl group having a thiol or thioether group in the molecule). (In the formula, R represents a nitrogen-containing heterocyclic group). (In the formula, R represents a monovalent residue).

  通过反应组分(a):四羧酸二酐;组分(b):作为胺组分，三胺和二胺的混合物(可以仅由三胺组成);以及组分(c):作为末端组分，从通式(1-1)到(1-4)中选择的化合物，可以获得与无机材料高效络合的终止修饰的多支化聚酰亚胺。 H2N-X-R1(1-1)(式中，X表示单键或具有1到3个碳原子的烷基基团，R1表示含氮杂环基团)。 H2N-X-R1(1-2)(式中，X如上定义，R1表示含硫杂环基团或分子中具有巯基或硫醚基团的芳基基团)。 (式中，R表示含氮杂环基团)。 (式中，R表示单价残基)。
• PROSTACYCLIN DERIVATIVES
  申请人：Masse Craig E.

  公开号：US20120270934A1

  公开（公告）日：2012-10-25

  This invention relates to novel prostacyclin derivatives and acceptable salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by prostacyclin, and in particular those diseases and conditions beneficially treated by dilators of systemic and pulmonary arterial vascular beds or by platelet aggregation inhibitors.

  本发明涉及新颖的前列环素衍生物及其可接受的盐。本发明还提供了包含本发明化合物的组合物，并使用这些组合物在治疗利于前列环素治疗的疾病和病况的方法中，特别是那些通过扩张系统和肺动脉血管床或通过抑制血小板聚集而有益地治疗的疾病和病况。
• Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
  申请人：Onyx Therapeutics, Inc.

  公开号：US20140105921A1

  公开（公告）日：2014-04-17

  This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors.

  本公开涉及一些化合物，这些化合物可用作环氧酮蛋白酶抑制剂的前药。
• DIARYLETHENE COMPOUNDS AND USES THEREOF
  申请人：SWITCH MATERIALS, INC.

  公开号：US20160083398A1

  公开（公告）日：2016-03-24

  A compound according to Formula IA and IB, reversibly convertible under photochromic and electrochromic conditions between a ring-open isomer A and a ring-closed isomer B is provided. For substitutent groups, Z is N, O or S; each R 1 is independently selected from the group consisting of H, or halo; each R 2 is independently selected from the group consisting of H, halo, a polymer backbone, alkyl or aryl; or, when both R 2 together form —CH═CH— and form part of a polymer backbone; each R 3 is independently selected from the group consisting of H, halo, alkyl, alkoxy, thioalkyl or aryl; each R 4 is aryl; and each R 5 is independently selected from the group consisting of H, halo, alkyl, alkoxy, thioalkyl or aryl.

  本发明提供了一种按照式IA和IB的化合物，在光致变色和电致变色条件下，可在环开放异构体A和环闭合异构体B之间可逆地转化。对于取代基，Z为N、O或S；每个R1独立地选自H或卤素；每个R2独立地选自H、卤素、聚合物骨架、烷基或芳基；或者，当两个R2一起形成-CH═CH-并形成聚合物骨架的一部分时；每个R3独立地选自H、卤素、烷基、烷氧基、硫代烷基或芳基；每个R4为芳基；每个R5独立地选自H、卤素、烷基、烷氧基、硫代烷基或芳基。
• Desferrithiocin analogs and uses thereof
  申请人：University of Florida Research Foundation, Incorporated

  公开号：US10010535B2

  公开（公告）日：2018-07-03

  Iron overload is associated with pathological conditions such as oxidative stress, transfusional iron overload, thalassemia, primary hemochromatosis, secondary hemochromatosis, diabetes, liver disease, heart disease, cancer, radiation injury, neurological or neurodegenerative disorder, Friedreich's ataxia (FRDA), macular degeneration, closed head injury, irritable bowel disease, and reperfusion injury. The present invention provides methods and pharmaceutical compositions using desferrithiocin analogs of Formulae (A) and (J) for treating and/or preventing these pathological conditions, metal (e.g., iron, aluminum, a lanthanide, or an actinide (e.g., uranium)) overload conditions, and infectious diseases (e.g., malaria).

  铁超载与氧化应激、输血铁超载、地中海贫血、原发性血色素沉着病、继发性血色素沉着病、糖尿病、肝病、心脏病、癌症、辐射损伤、神经或神经退行性疾病、弗里德里希共济失调（FRDA）、黄斑变性、闭合性头部损伤、肠易激性疾病和再灌注损伤等病理状况有关。本发明提供了使用式（A）和式（J）的去铁硫霉素类似物治疗和/或预防这些病理状况、金属（如铁、铝、镧系元素或锕系元素（如铀））过载状况和传染病（如疟疾）的方法和药物组合物。